Cue Biopharma, Inc.
CUE· Nasdaq
Released Aug 14, 2026, after the close
10-Q filed Aug 14, 2026, 45 days after period end · 0001193125-26-352128
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $7.88M | $2.95M | $2.66M | $1.38M |
| Net Income | -$153.07M | -$8.48M | -$10.17M | -$13.19M |
| EPS Diluted |
Cue Biopharma, Inc. · CIK 1645460 · Engraved from SEC EDGAR
| -$24.14 |
| -$2.67 |
| -$0.20 |
| -$0.29 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.